The design, synthesis, and microbiological investigation of tobramycin catecholate conjugates

dc.contributor.authorRebizant, Joseph
dc.contributor.examiningcommitteeKumar, Ayush (Microbiology)en_US
dc.contributor.examiningcommitteeDavis, Rebecca (Chemistry)en_US
dc.contributor.supervisorSchweizer, Frank
dc.date.accessioned2022-08-25T16:23:13Z
dc.date.available2022-08-25T16:23:13Z
dc.date.copyright2022-08-25
dc.date.issued2022-08-25
dc.date.submitted2022-08-25T10:41:10Zen_US
dc.degree.disciplineChemistryen_US
dc.degree.levelMaster of Science (M.Sc.)en_US
dc.description.abstractWith the ever-growing threat of multi-drug resistant (MDR) bacteria to the public health, there is a mounting need for the development of novel therapeutics to combat them. Sideromycins are an emerging approach to develop new therapeutics by covalently linking siderophore ligands to antibiotics. This allows these sideromycins to exploit the siderophore uptake mechanism that are fundamental to bacteria, allowing the antibiotic to transverse the bacterial membrane and bypass resistant factors, analogous to a Trojan Horse. Aminoglycosides are a class of broad-spectrum antibiotics that inhibit protein synthesis and are usually reserved for severe bacterial infections, especially those that are caused by Gram-negative bacteria. A common form of resistance against aminoglycoside that develop in clinically isolated Gram-negative bacteria, especially in Pseudomonas aeruginosa strains, is outer membrane impermeability to aminoglycosides. In theory, conjugation of aminoglycosides with a siderophore moiety will allow the aminoglycoside increased access to their intercellular target by exploiting the siderophore uptake system and bypassing impermeability resistance factors. In this study, a new series of aminoglycoside-siderophore conjugates are synthesized by conjugating the aminoglycoside tobramycin to 3,4-dihydroxybenzoic acid, a siderophore ligand, resulting in tobramycin-catecholate (TOB-CAT) conjugates. To elucidate the significance of the catecholate to the activity of the TOB-CAT conjugates, methoxy protected tobramycin-catecholate (TOB-mCAT) conjugates were also synthesized, where the added methoxy groups block the binding capabilities of the catecholate component. In vitro antibacterial studies in MHB show that these TOB-CAT conjugates have P. aeruginosa specific activity, reaching tobramycin susceptibility breakpoints in three P. aeruginosa clinically isolated strains. These studies also showed that the TOB-mCAT conjugates have no activity against the tested Gram-negative strains, indicating the catecholate for the activity observed by the TOB-CAT conjugates. In vitro antibacterial studies in iron deficient cation-adjusted MHB (ID-CAMHB) show a total loss of significant activity of the TOB-CAT conjugates against P. aeruginosa clinical isolates. In vitro combination studies indicate that both the TOB-CAT and TOB-mCAT conjugates are capable of synergizing legacy antibiotics, particularly novobiocin and rifampicin, against Gram-negative bacterial strains in MHB.en_US
dc.description.noteOctober 2022en_US
dc.identifier.urihttp://hdl.handle.net/1993/36769
dc.language.isoengen_US
dc.rightsopen accessen_US
dc.subjectAntibioticsen_US
dc.subjectAminoglycosidesen_US
dc.subjectTobramycinen_US
dc.subjectSiderophoresen_US
dc.subjectSiderophoreen_US
dc.subjectCatecholateen_US
dc.subjectConjugatesen_US
dc.subjectSynthesisen_US
dc.subjectSideromycinen_US
dc.subjectSideromycinsen_US
dc.subjectGram-negativeen_US
dc.subjectBacteriaen_US
dc.subjectResistanceen_US
dc.subjectResistanten_US
dc.subjectAntibacterialen_US
dc.subjectActivityen_US
dc.titleThe design, synthesis, and microbiological investigation of tobramycin catecholate conjugatesen_US
dc.typemaster thesisen_US
local.subject.manitobanoen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Rebizant_Joseph.pdf
Size:
7.6 MB
Format:
Adobe Portable Document Format
Description:
Thesis
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
2.2 KB
Format:
Item-specific license agreed to upon submission
Description: